Full-Time

Quality Assurance Senior Manager

GMP GDP Auditor

Posted on 8/28/2026

Deadline 9/12/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$124.4k - $207.4k/yr

+ 17.5% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Remote in USA + 1 more

More locations: New York, NY, USA

Remote

Remote field-based role with travel up to 60%, including domestic and international travel.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
GMP
Quality Assurance (QA)
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree with at least 6 years of experience, or a master's degree with at least 5 years of experience, or a PhD with 1 or more years of experience.
  • Advanced knowledge and understanding of global regulations, including the FDA, ICH, PICs, EMA, Health Canada, ANVISA, and TGA, and international standards including ISO and WHO.
  • Human oversight, professional judgment, and source verification when using artificial intelligence tools for audit planning, execution, reporting, and follow-up.
  • Willingness to adopt new audit technologies and contribute to continuous improvement of digital audit workflows and methodologies.
  • Comprehensive working knowledge of business concepts and quality operations within Pfizer.
  • Critical thinking expertise and the ability to define and implement a strategic audit approach based on compliance and business knowledge.
  • Strong knowledge and application of quality and auditing frameworks.
  • Proficient organizational and project management skills.
  • Ability to suggest new audit techniques and approaches and drive their implementation to improve audit systems.
  • Ability to identify trends within data and apply insights to make recommendations and decisions.
  • Ability to bring recommendations to stakeholders for discussion and input.
  • Ability to lead and progress efforts to deliver operational improvements.
  • Domain expertise in two or more technical areas, such as active pharmaceutical ingredients or solid oral dosage forms.
  • Ability to work with ambiguity and adapt plans when needed.
  • Ability to use and interpret qualitative and quantitative data to drive decision-making, operationalize recommendations, and understand potential impact on other business areas.
  • Specialist expertise in complex technologies, such as sterile biologics, small molecules, or medical device combination products.
  • Ability to travel up to 60% of the time, including domestic and international travel.
  • Authorization to be employed in the United States by any employer and permanent work authorization in the United States.
Responsibilities
  • Independently plan and lead complex audits of material suppliers, service providers, contract manufacturers, and Pfizer country offices with minimal oversight.
  • Perform initial, routine, for-cause audits and due-diligence assessments.
  • Support the creation, testing, refinement, and adoption of artificial-intelligence-enabled audit tools for responsible audit execution.
  • Use artificial intelligence tools to support targeted audit preparation and execution responsibly.
  • Execute audit strategy, lead process audits, and perform special assessments.
  • Review audit reports from outsourced or routine audits.
  • Assess audit plans and quality metrics to identify potential areas of risk.
  • Actively support regulatory inspections as needed.
  • Identify and drive audit process improvements.
  • Deliver awareness sessions on GMP topics internally and externally with manager oversight.
  • Drive interactions with quality assurance colleagues across Pfizer locations and organizations to ensure consistent application of quality assurance strategy and standardization of auditing approaches.
  • Engage in discussions to determine the impact of changing regulatory-environment needs.
  • Work with RQA colleagues on cross-GxP audit plans as required.
  • Coach colleagues and lead training for routine and non-routine site and process audits.
  • Advise business representatives on outcomes of complex audits and provide input to process-improvement activities.
  • Provide clients with influence and recommendations to meet changing GMP business needs independently and with minimal supervision.
Desired Qualifications
  • Working knowledge of data analytics and interpretation capabilities.
  • Stakeholder and conflict management, including communications and relationship management.
  • Ability to acquire feedback and negotiate audit outcomes with stakeholders and auditees.
  • Experience conducting audits with a background in GMP, process, or other related quality areas.
  • Expertise in vendor audits plus one technology area, such as medical device combination products, sterile biologics, small molecules, or good distribution practices.
  • Ability to function autonomously in a matrix model and in a team environment.
  • Experience providing training or mentorship to other auditors or subject-matter experts.
  • Ability to directly manage audit teams.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

INACTIVE